Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
Alamar Biosciences Inc ALMR
$32.80
▼ -1.20%
($-0.40)
Open
$33.40
Prev Close
$33.20
Day Range
$32.60 – $33.97
52W Range
$18.85 – $38.54
Market Cap
$2.28B
Beta
-0.10
📋 Company Profile
| Industry | Life Sciences Tools & Services |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-04-17 |
| Shares Out. | 69,310,000 |
| Website | alamarbio.com ↗ |
| Phone | 15106269888 |
| Revenue | $29.4M |
| Gross Profit | $17.7M |
| Net Income | -$13.2M |
| Total Assets | $391.0M |
| Total Liabilities | $78.1M |
| Equity | $312.9M |
About Alamar Biosciences Inc
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
Alamar Biosciences Inc is a publicly traded company under the ticker symbol ALMR on the NASDAQ NMS - GLOBAL MARKET, operating in the Life Sciences Tools & Services industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-09-01)